Ranolazine Cardioprotection in PCI

Harvey Hahn

Status and phase

Terminated

Phase 2

Conditions

Acute Coronary Syndrome

Treatments

Drug: Ranolazine

Drug: Placebo

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01767987

ISR IN-US-259-0139

Details and patient eligibility

About

The investigators will test if upfront dosing of Ranolazine can reduce myocardial biomarker release (CK-MB, Troponin) post percutaneous coronary intervention (PCI).

Full description

Ranolazine has been demonstrated to decrease angina, ischemia on perfusion imaging, improve diastolic function, and cardiac metabolism. Furthermore it has been associated with reduced cardiac arrhythmias, including non-sustained ventricular tachycardia and atrial fibrillation. It has not been studied as an acute cardioprotective agent in percutaneous coronary intervention (PCI).

We hypothesize that upfront administration of Ranolazine could decrease the myocardial injury associated with PCI due to all the factors listed above (i.e. precondition the myocardium). We plan to screen all patients scheduled for an elective coronary angiogram. Those who meet criteria and consent will be randomized to either receive Ranolazine or placebo twice a day for 3 days leading up to the PCI.

Enrollment

6 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 18 or older
Patients undergoing Coronary Angiography with possible PCI
Able and willing to give consent
Able to read and write English

Exclusion criteria

Current EKG or Biomarker of Acute Myocardial Infarction (MI) or Acute Coronary Syndromes (ACS)
History of Allergy to Ranolazine
Pregnant or Nursing
Currently taking Ranolazine